|
Acute pancreatitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Soluble urokinase plasminogen activator receptor is of good predictive value for SAP risk and may serve as a potential biomarker for disease severity, inflammation, and inhospital mortality in SAP patients.
|
31774228 |
2020 |
|
Childhood Acute Lymphoblastic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Disordered hemostasis associated with severely depressed fibrinolysis demonstrated using a simultaneous thrombin and plasmin generation assay during L-asparaginase induction therapy in pediatric acute lymphoblastic leukemia.
|
31556233 |
2020 |
|
Nodule
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Novel LRAP-binding partner revealing the plasminogen activation system as a regulator of cementoblast differentiation and mineral nodule formation in vitro.
|
31621902 |
2020 |
|
Androgen-Insensitivity Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
Numerous polymorphic variants of genes encoding proteins, that is, plasminogen activator inhibitor as well as coagulation factors, involved in the coagulation cascade may be related to arterial ischemic stroke (AIS) both in adults and children.
|
31530188 |
2020 |
|
Non-small cell lung cancer stage I
|
0.010 |
Biomarker
|
disease |
BEFREE |
By comparing urine samples with matching plasma CEA from NSCLC stage I-IV patients (n=81) and healthy controls (n=31), the combination of CEA with PLG or FGG showed that the AUC was 0.889 and 0.806, respectively, which is superior to a single biomarker alone.
|
31821791 |
2020 |
|
Arteriosclerosis Obliterans
|
0.010 |
Biomarker
|
disease |
BEFREE |
Efficacy of trimetazidine and plasmin combined with alprostadil in treatment of lower extremity arteriosclerosis obliterans.
|
31086587 |
2019 |
|
Bacterial Infections
|
0.010 |
Biomarker
|
group |
BEFREE |
The interaction of two novel putative proteins of <i>Leptospira interrogans</i> with E-cadherin, plasminogen and complement components with potential role in bacterial infection.
|
31422744 |
2019 |
|
Carotid Artery Thrombosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
MS-1 possessed markedly thrombolytic activity evaluated by plasminogen activator inhibitior-1, fibrin degradation products, and D-dimer levels using rats plasma, and recanalization rate by FeCl<sub>3</sub>-induced carotid artery thrombosis in mice.
|
31027312 |
2019 |
|
Brain Ischemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The objectives of the present were twofold: first, to characterize the time-dependent cerebral mRNA expression of the plasminogen activator system (PAS) after brain ischemia and second, to investigate the impact of PAI-1 and PAI-2 on brain infarct volume using gene-deficient mice.
|
29978354 |
2019 |
|
Fascioliasis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Numerous Fasciola plasminogen-binding proteins may underlie blood-brain barrier leakage and explain neurological disorder complexity and heterogeneity in the acute and chronic phases of human fascioliasis.
|
30246668 |
2019 |
|
Hematological Disease
|
0.010 |
Biomarker
|
group |
BEFREE |
Expression of the urokinase-type plasminogen activation system including urokinase (uPA) and its receptor (uPAR) has been associated with the complex process of cell migration, a tumour's invasive potential as well as a reduced overall and disease-free survival of patients with solid cancers and haematological disorders.
|
30970388 |
2019 |
|
Lupus Nephritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Of the coagulation cascade proteins surveyed, urine plasmin emerges as the strongest predictor of eGFR and clinical renal disease in patients with LN.
|
31319876 |
2019 |
|
Psychotic Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Role of tissue plasminogen activator and plasminogen activator inhibitor as potential biomarkers in psychosis.
|
31125952 |
2019 |
|
Syphilis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Positive syphilis serology (rapid plasmin reagin) was found in 29%-31% of HIV+ FSWs and 9%-12% of HIV- FSWs and SMs.
|
31204869 |
2019 |
|
Polycystic Kidney, Autosomal Dominant
|
0.010 |
Biomarker
|
disease |
BEFREE |
Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease.
|
31171572 |
2019 |
|
Carcinoma breast stage IV
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, PLG-CA4 induces the polarization of tumor-associated macrophages (TAMs) toward the M2-like phenotype in 4T1 metastatic breast cancer (Control 30% vs PLG-CA4 53%; <i>p</i> < 0.05).
|
31380170 |
2019 |
|
Anastomosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
PLG is deposited rapidly and specifically at the site of colorectal anastomoses.
|
31851007 |
2019 |
|
Nonorganic psychosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Role of tissue plasminogen activator and plasminogen activator inhibitor as potential biomarkers in psychosis.
|
31125952 |
2019 |
|
Secondary malignant neoplasm of liver
|
0.010 |
Biomarker
|
disease |
BEFREE |
Further statistical analysis revealed 47 proteins exhibiting statistical significance between localized and metastatic CRCs, of which FILI1P1 and PLG were identified for the first time in proteomic data, which were highly associated with liver metastasis in CRCs.
|
31781478 |
2019 |
|
Middle Cerebral Artery Occlusion
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b>Methods:</b> C57Bl/6J wild-type mice and plasminogen-deficient (plg<sup>-/-</sup>) mice were subjected to middle cerebral artery occlusion (MCAo) for 60 min followed by mouse t-PA treatment (0.9 mg/kg) at reperfusion.
|
30972077 |
2019 |
|
cardiac event
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Soluble urokinase plasminogen activator receptor in one-year prediction of major adverse cardiac events in patients after first myocardial infarction treated with primary percutaneous coronary intervention.
|
30697255 |
2019 |
|
First myocardial infarction
|
0.010 |
Biomarker
|
disease |
BEFREE |
Soluble urokinase plasminogen activator receptor level appears to be an independent useful biomarker for the prediction of major adverse cardiac events early after first myocardial infarction.
|
30697255 |
2019 |
|
Dystrophia myotonica 2
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Type 2 diabetes mellitus (DM2) is associated with coronary heart disease (CHD) and is characterized by high levels of plasminogen activator inhibitor (PAI)-1.
|
31760103 |
2019 |
|
Heart failure with normal ejection fraction
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results suggest a possible link between PLG-SAS and heart failure with preserved ejection fraction in some symptomatic patients.
|
30617000 |
2019 |
|
Cone-Rod Dystrophy 2
|
0.010 |
Biomarker
|
disease |
BEFREE |
The results of the present study identified PTPRC, F2 and PLG as potential targets for SCI treatment, which may further improve the general understanding of SCI pathology.
|
30747207 |
2019 |